GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.
企業コードWGS
会社名GeneDx Holdings Corp
上場日Sep 04, 2020
最高経営責任者「CEO」Ms. Katherine A. Stueland
従業員数1000
証券種類Ordinary Share
決算期末Sep 04
本社所在地333 Ludlow Street
都市STAMFORD
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号06902
電話番号18887291206
ウェブサイトhttps://sema4.com/
企業コードWGS
上場日Sep 04, 2020
最高経営責任者「CEO」Ms. Katherine A. Stueland
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし